MIM
ORIC icon

MetLife Investment Management’s Oric Pharmaceuticals ORIC Stock Holding History

MetLife Investment Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$475K Buy
43,840
+8,151
+23% +$73.9K ﹤0.01% 1939
2026
Q1 		$452K Buy
35,689
+1,719
+5% +$19.5K ﹤0.01% 1802
2025
Q4 		$278K Hold
33,970
– – ﹤0.01% 2109
2025
Q3 		$408K Buy
33,970
+6,898
+25% +$72.6K ﹤0.01% 1905
2025
Q2 		$275K Sell
27,072
-13,784
-34% -$92.5K ﹤0.01% 2009
2025
Q1 		$228K Sell
40,856
-752
-2% -$6.58K ﹤0.01% 2128
2024
Q4 		$336K Buy
41,608
+5,530
+15% +$50.7K ﹤0.01% 2008
2024
Q3 		$370K Hold
36,078
– – ﹤0.01% 1950
2024
Q2 		$255K Buy
36,078
+15,341
+74% +$137K ﹤0.01% 2096
2024
Q1 		$285K Hold
20,737
– – ﹤0.01% 1983
2023
Q4 		$191K Hold
20,737
– – ﹤0.01% 2271
2023
Q3 		$125K Hold
20,737
– – ﹤0.01% 2468
2023
Q2 		$161K Buy
+20,737
New +$118K ﹤0.01% 2402
2022
Q1 		– Sell
-11,317
Closed -$166K – 2757
2021
Q4 		$166K Hold
11,317
– – ﹤0.01% 2171
2021
Q3 		$237K Buy
11,317
+1,866
+20% +$37.8K ﹤0.01% 1985
2021
Q2 		$167K Hold
9,451
– – ﹤0.01% 2262
2021
Q1 		$232K Hold
9,451
– – ﹤0.01% 1974
2020
Q4 		$320K Buy
+9,451
New +$271K ﹤0.01% 1727
2020
Q3 		– Sell
-4,615
Closed -$156K – 2324
2020
Q2 		$156K Buy
+4,615
New +$147K ﹤0.01% 2039

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MetLife Investment Management's ORIC Position: Q2 2026 in Review

MetLife Investment Management increased its Oric Pharmaceuticals (ORIC) stake by 23% in Q2 2026, buying an estimated $73.9K and bringing the position to 43,840 shares worth $475K. The position accounts for ﹤0.01% of the portfolio, ranked #1939.

MetLife Investment Management first reported a position in ORIC in Q2 2020 and has held it in 19 quarters since. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • MetLife Investment Management held 43,840 shares of Oric Pharmaceuticals worth $475K as of Q2 2026.
  • MetLife Investment Management bought 8,151 Oric Pharmaceuticals shares in Q2 2026, an estimated $73.9K.
  • Oric Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1939 holding.
  • MetLife Investment Management first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 19 quarters since.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.